Starling Oncology, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Starling Oncology, Inc. (DFPH) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $12.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-12
- Starling Oncology, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $12.36M, a 28.50% increase from fiscal 2024.
- Starling Oncology, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $9.62M, a 49.56% decline from fiscal 2023.
- Starling Oncology, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $19.06M, a 5.61% decline from fiscal 2022.
- Starling Oncology, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $20.20M, a 117.91% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $12.36M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $9.62M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $19.06M 10-K · filed 2025-03-26 | |
| 2022-12-31 | $20.20M 10-K · filed 2024-03-28 | |
| 2021-12-31 | $9.27M 10-K · filed 2023-03-16 | |
| 2020-12-31 | $3.60M 10-K · filed 2022-03-11 | $101.68K 10-K · filed 2021-03-30 |
| 2019-12-31 | $483.00 10-K/A · filed 2021-12-14 |